Partsch Carl-Joachim, Sippell Wolfgang G
Division of Paediatric Endocrinology, Department of Paediatrics, Kinderklink, Christian Albrechts-Universität zu Kiel, Schwanenweg 20, D-24105 Kiel, Germany.
Best Pract Res Clin Endocrinol Metab. 2002 Mar;16(1):165-89. doi: 10.1053/beem.2002.0188.
This chapter describes several aspects of the management of treatment in girls and boys with central precocious puberty. Although there is some controversy about the indication for gonadotrophin releasing hormone (GnRH) agonist treatment in the literature, a list of clear indications is presented and monitoring requirements for treatment are discussed with reference to the pertinent literature. The development of clinical, psychological, hormonal, sonographical and auxological parameters that can be expected during GnRH agonist treatment is described in detail. In view of the scant evidence-based knowledge, we review the final outcome of patients treated with GnRH agonists with respect to reversibility of hormonal suppression, reproductive function, final height and side effects. The data published so far show that GnRH agonist treatment using the modern depot preparations is not only convenient but also safe, with relatively minor side effects. The outcome in terms of final height is favourable in the majority of patients.
本章描述了中枢性性早熟女童和男童治疗管理的几个方面。尽管文献中对于促性腺激素释放激素（GnRH）激动剂治疗的适应证存在一些争议，但本文列出了明确的适应证清单，并参考相关文献讨论了治疗的监测要求。详细描述了GnRH激动剂治疗期间可能出现的临床、心理、激素、超声和体格学参数的变化。鉴于基于证据的知识匮乏，我们回顾了接受GnRH激动剂治疗的患者在激素抑制的可逆性、生殖功能、最终身高和副作用方面的最终结局。迄今为止发表的数据表明，使用现代长效制剂进行GnRH激动剂治疗不仅方便，而且安全，副作用相对较小。大多数患者的最终身高结局良好。
